MedTrace Logo

BMS-986012 in Relapsed/Refractory SCLC

NCT02247349 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2024-03-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986012 alone and in combination with nivolumab in patients with relapsed/refractory SCLC.

Conditions

Interventions

BIOLOGICAL

BMS-986012 (anti-fucosyl-GM1)

BIOLOGICAL

Nivolumab

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-14
Primary Completion
2022-12-21
Completion
2022-12-22

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • Netherlands
  • Puerto Rico
  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02247349 on ClinicalTrials.gov